Acción Iteos Therapeutics (ITOS)

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. It is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.